Diabetic ketoacidosis after treatment with pembrolizumab

Aaziz Mhariz; Isuru P. Fernando; Anjan Lenkanpally; Devaka J. S. Fernando

doi:10.1016/j.jecr.2017.05.002

Diabetic ketoacidosis after treatment with pembrolizumab

Aaziz Mhariz, Isuru P. Fernando, Anjan Lenkanpally, Devaka J. S. Fernando

Western Sydney University

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Abstract

Immune checkpoint inhibiting agents have been shown to precipitate type 1 diabetes. We report a case of acute severe diabetic ketoacidosis in a patient with no history of diabetes who developed ketoacidosis after starting anti-PD1 immunotherapy with Pembrolizumab. Key Words Immune Checkpoint inhibitors, Pembrolizumab, Diabetic Ketoacidosis, Melanoma, Programmed Cell Death receptor, Anti PD1, PD 1 Inhibitor Introduction Pembrolizumab is a monoclonal antibody mainly used in the treatment of advanced/metastatic malignant melanoma (and also historically less responsive tumour types) [1] that acts by blocking the inhibitory ligand (PDL1) of the PD1 (programmed cell death 1) receptor. Anti-PD-1 therapy has been shown to precipitate type 1 diabetes in non-obese diabetic mice models [2] and only recently has diabetic keto-acidosis (DKA) secondary to PD1 antibody use been reported in humans [3–5].

Original language	English
Pages (from-to)	4-5
Number of pages	2
Journal	Journal of Clinical and Translational Endocrinology: Case Reports
Volume	5
DOIs	https://doi.org/10.1016/j.jecr.2017.05.002
Publication status	Published - 2017

Open Access - Access Right Statement

Keywords

complications
diabetes
immunotherapy
ketoacidosis

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jecr.2017.05.002

Cite this

@article{9de2b684fbe5473ba6c4c9b29e07b0a6,

title = "Diabetic ketoacidosis after treatment with pembrolizumab",

abstract = "Immune checkpoint inhibiting agents have been shown to precipitate type 1 diabetes. We report a case of acute severe diabetic ketoacidosis in a patient with no history of diabetes who developed ketoacidosis after starting anti-PD1 immunotherapy with Pembrolizumab. Key Words Immune Checkpoint inhibitors, Pembrolizumab, Diabetic Ketoacidosis, Melanoma, Programmed Cell Death receptor, Anti PD1, PD 1 Inhibitor Introduction Pembrolizumab is a monoclonal antibody mainly used in the treatment of advanced/metastatic malignant melanoma (and also historically less responsive tumour types) [1] that acts by blocking the inhibitory ligand (PDL1) of the PD1 (programmed cell death 1) receptor. Anti-PD-1 therapy has been shown to precipitate type 1 diabetes in non-obese diabetic mice models [2] and only recently has diabetic keto-acidosis (DKA) secondary to PD1 antibody use been reported in humans [3–5].",

keywords = "complications, diabetes, immunotherapy, ketoacidosis",

author = "Aaziz Mhariz and Fernando, {Isuru P.} and Anjan Lenkanpally and Fernando, {Devaka J. S.}",

year = "2017",

doi = "10.1016/j.jecr.2017.05.002",

language = "English",

volume = "5",

pages = "4--5",

journal = "Journal of Clinical and Translational Endocrinology: Case Reports",

issn = "2214-6245",

publisher = "Elsevier",

}

TY - JOUR

T1 - Diabetic ketoacidosis after treatment with pembrolizumab

AU - Mhariz, Aaziz

AU - Fernando, Isuru P.

AU - Lenkanpally, Anjan

AU - Fernando, Devaka J. S.

PY - 2017

Y1 - 2017

N2 - Immune checkpoint inhibiting agents have been shown to precipitate type 1 diabetes. We report a case of acute severe diabetic ketoacidosis in a patient with no history of diabetes who developed ketoacidosis after starting anti-PD1 immunotherapy with Pembrolizumab. Key Words Immune Checkpoint inhibitors, Pembrolizumab, Diabetic Ketoacidosis, Melanoma, Programmed Cell Death receptor, Anti PD1, PD 1 Inhibitor Introduction Pembrolizumab is a monoclonal antibody mainly used in the treatment of advanced/metastatic malignant melanoma (and also historically less responsive tumour types) [1] that acts by blocking the inhibitory ligand (PDL1) of the PD1 (programmed cell death 1) receptor. Anti-PD-1 therapy has been shown to precipitate type 1 diabetes in non-obese diabetic mice models [2] and only recently has diabetic keto-acidosis (DKA) secondary to PD1 antibody use been reported in humans [3–5].

AB - Immune checkpoint inhibiting agents have been shown to precipitate type 1 diabetes. We report a case of acute severe diabetic ketoacidosis in a patient with no history of diabetes who developed ketoacidosis after starting anti-PD1 immunotherapy with Pembrolizumab. Key Words Immune Checkpoint inhibitors, Pembrolizumab, Diabetic Ketoacidosis, Melanoma, Programmed Cell Death receptor, Anti PD1, PD 1 Inhibitor Introduction Pembrolizumab is a monoclonal antibody mainly used in the treatment of advanced/metastatic malignant melanoma (and also historically less responsive tumour types) [1] that acts by blocking the inhibitory ligand (PDL1) of the PD1 (programmed cell death 1) receptor. Anti-PD-1 therapy has been shown to precipitate type 1 diabetes in non-obese diabetic mice models [2] and only recently has diabetic keto-acidosis (DKA) secondary to PD1 antibody use been reported in humans [3–5].

KW - complications

KW - diabetes

KW - immunotherapy

KW - ketoacidosis

UR - http://handle.westernsydney.edu.au:8081/1959.7/uws:40972

U2 - 10.1016/j.jecr.2017.05.002

DO - 10.1016/j.jecr.2017.05.002

M3 - Article

SN - 2214-6245

VL - 5

SP - 4

EP - 5

JO - Journal of Clinical and Translational Endocrinology: Case Reports

JF - Journal of Clinical and Translational Endocrinology: Case Reports

ER -

Diabetic ketoacidosis after treatment with pembrolizumab

Abstract

Open Access - Access Right Statement

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this